4-氯-2,6-双(三氟甲基)嘧啶 | 779-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-氯-2,6-双(三氟甲基)嘧啶
• 英文名称: 6-Chlor-2,4-bis-trifluormethylpyrimidin
• 英文别名: 4-chloro-2,6-bis-trifluoromethyl-pyrimidine；4-Chloro-2,6-bis(trifluoromethyl)pyrimidine
• CAS: 779-86-2
• 化学式: C₆HClF₆N₂
• 分子量: 250.531
• InChiKey: QPAXSFCARCIQEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  sodium cyanide 、 4-氯-2,6-双(三氟甲基)嘧啶 在 三乙烯二胺 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  [EN] PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL
  [FR] COMPOSÉ PYRIMIDINE ET SON UTILISATION DANS LA LUTTE ANTIPARASITAIRE

  摘要：

  以下公式（I）所代表的嘧啶化合物对害虫具有出色的控制活性，并可用作杀虫剂的活性成分。

  公开号：

  WO2010134478A1
• 作为产物：
  描述：

  2,6-双(三氟甲基)嘧啶-4-醇 在 N,N-二甲基甲酰胺 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 4-氯-2,6-双(三氟甲基)嘧啶
  参考文献：
  名称：

  [EN] PYRIMIDINE COMPOUND AND ITS USE IN PEST CONTROL
  [FR] COMPOSÉ PYRIMIDINE ET SON UTILISATION DANS LA LUTTE ANTIPARASITAIRE

  摘要：

  以下公式（I）所代表的嘧啶化合物对害虫具有出色的控制活性，并可用作杀虫剂的活性成分。

  公开号：

  WO2010134478A1

文献信息

• [EN] AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS<br/>[FR] AMINOPYRIMIDINES COMME INHIBITEURS DE SORBITOL DESHYDROGENASE
  申请人：PFIZER PROD INC

  公开号：WO2000059510A1

  公开（公告）日：2000-10-12

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula (I), wherein R?1, R2 and R3¿ are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefor at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula (I) of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula (I) and to processes for preparing those intermediates.

  本发明涉及式（I）的山梨醇脱氢酶抑制剂，其中R1、R2和R3在说明书中定义。本发明还涉及含有这些化合物的药物组合物，以及通过将这些化合物用于患有糖尿病并因此有患上这些并发症风险的哺乳动物进行治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病的方法。本发明还涉及一种包含本发明式（I）化合物和醛还原酶抑制剂的药物组合物以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种包含本发明式（I）化合物和NHE-1抑制剂的药物组合物以及用于治疗心肌病和其他心脏相关问题的方法。本发明还涉及用于合成式（I）化合物的某些中间体以及制备这些中间体的方法。
• Sorbitol dehydrogenase inhibitors
  申请人：——

  公开号：US20040077671A1

  公开（公告）日：2004-04-22

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, 1 wherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  本发明涉及公式I的山梨醇脱氢酶抑制剂，其中R1、R2和R3如规范中所定义。本发明还涉及含有这些化合物的制药组合物以及通过向患有糖尿病且因此有发展这些并发症风险的哺乳动物投与这些化合物来治疗或预防糖尿病并发症，特别是糖尿病神经病、糖尿病肾病、糖尿病微血管病、糖尿病大血管病和糖尿病心肌病的方法。本发明还涉及一种公式I化合物与醛糖还原酶抑制剂的组合物制药组合物以及用于治疗或预防糖尿病并发症的方法。本发明还涉及一种公式I化合物与NHE-1抑制剂的组合物制药组合物以及用于治疗心肌病和其他心脏相关问题的方法。本发明还涉及用于合成公式I化合物的某些中间体以及制备这些中间体的方法。
• Salts of zopolrestat
  申请人：——

  公开号：US20010056095A1

  公开（公告）日：2001-12-27

  This invention relates to [4-oxo-(5-trifluoromethyl-benzothiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid ethanolamine salt, pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to said mammals said salt and said compositions. This invention is also directed to combinations of said diethylamine salt with NHE-1 inhibitors, selective serotonin retuptake inhibitors (SSRIs), glycogen phosphorylase inhibitors (GPIs), sorbitol dehydrogenase inhibitors (SDIs) and antihypertensive agents. Said combinations are useful in treating diabetic complications in mammals.

  本发明涉及[4-氧代-(5-三氟甲基苯并噻唑-2-基甲基)-3,4-二氢-邻苯二氮平-1-基]-乙酸乙醇胺盐，以及其制药组合物和治疗哺乳动物糖尿病并发症的方法，包括向该哺乳动物施用该盐和该组合物。本发明还涉及将该二乙酰胺盐与NHE-1抑制剂、选择性5-羟色胺再摄取抑制剂（SSRIs）、糖原磷酸化酶抑制剂（GPIs）、山梨醇脱氢酶抑制剂（SDIs）和降压药物组合的方法。该组合物在治疗哺乳动物糖尿病并发症方面具有用途。
• Combination of statins and sorbitol dehydrogenase inhibitors
  申请人：——

  公开号：US20030186994A1

  公开（公告）日：2003-10-02

  This invention relates to pharmaceutical compositions comprising combinations of a statin, a prodrug thereof or a pharmaceutically acceptable salt of said statin or said prodrug and a sorbitol dehydrogenase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said sorbitol dehydrogenase inhibitor or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from atherosclerosis and/or diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.

  本发明涉及药物组合物，其包含他汀类药物、其原药或所述他汀类药物或所述原药的药学上可接受的盐与山梨醇脱氢酶抑制剂、其原药或所述山梨醇脱氢酶抑制剂或所述原药的药学上可接受的盐的组合、含有此类组合物的试剂盒，以及使用此类组合物治疗哺乳动物（包括人类）动脉粥样硬化和/或糖尿病并发症（如糖尿病神经病变、糖尿病肾病变、糖尿病心肌病变、糖尿病视网膜病变、糖尿病微血管病变、糖尿病大血管病变、白内障或足部溃疡）的方法。
• AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1185275A1

  公开（公告）日：2002-03-13